Trademark and Brand Protection Notice

MYTRT is one invented word. It has no intended dictionary meaning, is not an acronym, and is not presented as a combination of separate words. Elevate Healthcare Group Limited owns the MYTRT word mark and associated goodwill. Unauthorised use that causes confusion, impersonates the service or misleads patients may be challenged through platform, registrar, domain-dispute, regulatory or court procedures as appropriate.

This notice explains ownership, permitted references, prohibited impersonation, reporting and potential enforcement. It does not predetermine whether a particular use is unlawful; trademark disputes depend on the facts, territory, goods or services, likelihood of confusion, legitimate-use defences and applicable law.

1. Owner and nature of the mark

Elevate Healthcare Group Limited, company number 16231959, owns the MYTRT brand and word mark. Its registered office is 71–75 Shelton Street, London, England, WC2H 9JQ.

MYTRT is a singular, coined word chosen as a distinctive brand identifier. It has no intended standalone lexical meaning. It is not an abbreviation or acronym and should not be divided, expanded or represented as generic terminology associated with a category of healthcare.

The mark may appear as MYTRT, MYTRT®, in a logo, or in another authorised brand treatment. Differences in capitalisation or styling do not authorise a third party to use a confusingly similar sign.

2. Registration status

Territory or system	Record	Publication-safe status at 7 August 2026
United Kingdom	UK trade mark UK00004202923 [5]	Registered word mark owned by Elevate Healthcare Group Limited; filed 13 May 2025 and registered 15 August 2025
WIPO Madrid System	International registration 1915762	Active international registration owned by Elevate Healthcare Group Limited; registered 11 November 2025, expiring 11 November 2035; classes 5 and 44 [1]
European Union	Madrid designation / EUIPO territorial record	International protection has been sought or designated; this notice does not state that final EU protection has been granted unless and until the current EUIPO/WIPO record confirms it
United States	USPTO serial 79449213	Pending Madrid-based application in classes 005 and 044; no US registration number is shown in the official search record at the date above [2]

The international specification includes relevant pharmaceutical, hormone-related, healthcare, clinic, pharmacy, phlebotomy, blood-testing and medical-laboratory goods or services. The scope enforceable in any country depends on that territory’s current record, examination, limitations and law.

A statement that MYTRT is “protected internationally” means that rights and applications exist through the UK and Madrid systems; it does not mean that every designation has completed territorial examination or that identical rights exist in every country.

3. Uses requiring written permission

Unless the law independently permits the use, prior written permission is required to use MYTRT or a confusingly similar sign as or within:

• a company, trading, clinic, pharmacy, product, protocol, app or service name;
• a domain name, subdomain, social-media handle, channel or account name;
• a logo, badge, certification, endorsement statement or partnership claim;
• product packaging, medicine packaging, a test kit, prescription document or patient communication;
• a marketplace listing, affiliate page, paid advertisement, search advertisement, metatag or source code intended to divert or confuse users;
• a conference, publication, training course, membership programme or promotional campaign suggesting affiliation; or
• software, data, an AI assistant or another interface presented as an official MYTRT service.

Permission must be obtained from an authorised representative of Elevate Healthcare Group Limited. Silence, a previous purchase, an informal conversation, a website link or access to brand assets is not permission.

4. Fair and legitimate reference

Trademark law may permit accurate, necessary and non-misleading reference. Examples can include genuine journalism, commentary, criticism, comparison, a patient complaint, an academic discussion, a regulator’s publication, or identification of an authentic service.

A person making such a reference should:

1. use only as much of the mark as is reasonably necessary;
2. distinguish their material clearly from an official MYTRT page or communication;
3. avoid a logo or presentation that implies sponsorship or partnership;
4. not alter the mark to create confusion or ridicule a patient or protected group;
5. ensure factual claims are supportable; and
6. include a clarification such as “not affiliated with or endorsed by MYTRT” where confusion may otherwise arise.

This notice does not restrict lawful consumer speech, complaints, whistleblowing, regulatory reporting, comparative advertising that meets legal requirements, or another defence available under applicable law.

5. Counterfeit, impersonation and patient-safety risks

Misuse can create more than brand confusion. A counterfeit clinic, medicine, test, prescription, result, email, telephone number, website or account may expose people to fraud, privacy loss or unsafe care.

Warning signs include:

• a domain, email or social account that closely imitates MYTRT but uses an unexpected address;
• a request to pay an individual, cryptocurrency address or bank account not shown in an authorised checkout;
• an unsolicited prescription or medicine offered without an appropriate clinical assessment;
• use of MYTRT branding on packaging, reports or certificates that cannot be verified;
• a claim of partnership, accreditation or employment not confirmed through an official channel; or
• a request for passwords, one-time codes or excessive clinical information through an unverified message.

Do not use a suspected medicine or rely on a suspected clinical document. Contact help@mytrt.com or 0800 157 7521 through details independently obtained from www.mytrt.com. If someone is in immediate danger, call 999.

6. Reporting suspected misuse

Send a report to help@mytrt.com with the subject “Trademark report”. Where available, include:

Evidence	Examples
Location	Full URL, domain, app-store page, marketplace listing, social handle or physical location
Record	Screenshot, photograph, advertisement, email header or packaging image
Timing	Date and time first seen and whether the material remains live
Identity	Seller, account, company, registrar or host information visible to you
Concern	How the use may cause confusion, impersonation, fraud, counterfeiting or patient-safety risk
Your contact	A safe method for follow-up; anonymous reports will still be considered where evidence permits

Do not hack an account, misrepresent yourself, purchase a suspected controlled medicine, trespass, or obtain private information unlawfully to gather evidence.

We may acknowledge a sufficiently detailed report, but confidentiality, privilege, investigation integrity and data-protection duties may prevent us from sharing every action or outcome.

7. How we assess a report

We may consider:

• similarity of the sign, presentation and overall impression;
• territory and current registration or application status;
• goods, services, audience and channels;
• actual or likely confusion;
• evidence of impersonation, diversion, bad faith, counterfeiting or patient harm;
• fair use, descriptive use, criticism, parody, exhaustion, nominative use or another legal defence;
• urgency, proportionality and whether a correction or clarification can resolve the issue; and
• the rules of the relevant platform, registrar, registry, marketplace or dispute forum.

We do not assume that every use of the letters within MYTRT infringes our rights. Assessment is evidence-based.

8. Potential enforcement action

Depending on the circumstances, Elevate Healthcare Group Limited may:

1. request clarification, correction, transfer or voluntary removal;
2. send a cease-and-desist or evidence-preservation notice;
3. report impersonation, counterfeiting, fraud, unsafe medicines or misleading advertising to a platform, marketplace, search provider, app store, host, payment provider, professional regulator or public authority;
4. use a registrar’s or registry’s published abuse and rights-protection process;
5. commence a Uniform Domain-Name Dispute-Resolution Policy (UDRP) complaint for an alleged abusive domain registration;
6. use the Uniform Rapid Suspension (URS) procedure for an eligible, clear-cut case where suspension is the available remedy;
7. seek an injunction, delivery up, disclosure, damages, an account of profits, costs or another remedy from a competent court; or
8. refer suspected crime, medicine counterfeiting, identity theft or patient-safety issues to the appropriate authority.

ICANN explains that most trademark-based domain disputes are resolved by agreement, court action or a proceeding filed with an approved dispute-resolution provider before a registrar will cancel, suspend or transfer a domain. [3] URS is a complementary, faster route for eligible clear-cut cases and normally concerns suspension rather than transfer. [4] We therefore do not describe a general email to ICANN as an automatic “takedown.”

We choose action proportionately. Nothing in this notice requires enforcement in every case or waives a right if action is not taken immediately.

9. Domains, search and platform notices

A notice sent to a registrar, host, search provider, marketplace or social platform will identify the right relied on, the disputed material, the requested action and supporting evidence to the extent reasonably required. We will not knowingly submit a materially false notice.

The recipient applies its own terms and legal duties. It may reject the notice, request more evidence, preserve content, restrict visibility, suspend an account, disclose information where lawful, or require a court or dispute-resolution order.

A person affected by a notice should use the recipient’s counter-notice, appeal or review process and may contact help@mytrt.com with evidence of authorisation, legitimate use, mistaken identity or another defence.

10. No transfer of rights

Nothing in this notice, the Website Terms, a purchase or a complaint transfers ownership of the MYTRT mark, logo, domain names, designs, copyright or goodwill. Any express licence must be in writing, state its scope, territory, purpose and duration, and may impose brand, quality, regulatory and termination requirements.

11. Contact

Purpose	Contact
Permission or licensing request	help@mytrt.com — subject: Brand permission
Suspected misuse	help@mytrt.com — subject: Trademark report
Telephone	0800 157 7521, Monday–Saturday, 8am–6pm
Post	Elevate Healthcare Group Limited, 71–75 Shelton Street, London, England, WC2H 9JQ

A patient or customer complaint about MYTRT should use the Complaints Policy rather than the trademark-reporting route.

References

1. WIPO Madrid Monitor — MYTRT international registration 1915762
2. USPTO Trademark Search — MYTRT serial 79449213
3. ICANN — Uniform Domain-Name Dispute-Resolution Policy
4. ICANN — Uniform Rapid Suspension
5. UK Intellectual Property Office — UK00004202923